Leuprolide

What it is

Leuprolide (sold as Lupron) is a synthetic hormone drug that works by flooding the body's hormone-control system until it shuts down, causing a sharp and sustained drop in sex hormone production. It is an FDA-approved prescription medication used to treat prostate cancer, endometriosis, uterine fibroids, and early-onset puberty in children; it is also studied for premenstrual dysphoric disorder and gender-affirming puberty suppression.

The scientific side

Leuprolide is a synthetic nonapeptide analog of the endogenous gonadotropin-releasing hormone (GnRH, also called LHRH) that acts as a potent GnRH receptor agonist. Under normal physiology, GnRH is released from the hypothalamus in short pulses, stimulating the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn signal the gonads to produce testosterone in men and estrogen in women. Leuprolide disrupts this pulsatile signaling through paradoxical receptor downregulation: continuous, non-pulsatile GnRH receptor stimulation causes the pituitary gonadotroph cells to desensitize and markedly reduce LH and FSH secretion. The resulting suppression of gonadal sex hormone production — testosterone in men and estrogen in women — is profound and reversible upon discontinuation. In men with prostate cancer, the initial 1–2 weeks of leuprolide administration produce a transient 'testosterone surge' (a short-lived spike in LH and testosterone before downregulation takes effect), which can transiently worsen tumor symptoms ('clinical flare'); this is a pharmacological distinguishing feature compared to GnRH antagonists such as degarelix, which suppress testosterone immediately without a surge. After the initial surge, sustained leuprolide therapy reduces serum testosterone to castrate levels (≤0.5 ng/mL) in the vast majority of patients — 96.4% achieving castration at 12 months in a phase III trial versus leuprolide 7.5 mg monthly. In the HERO phase 3 trial (N=930), leuprolide injections every 12 weeks achieved sustained castration in 88.8% of men over 48 weeks, while testosterone recovery after stopping treatment was substantially delayed compared to the GnRH antagonist relugolix (58.6 ng/dL vs. 288.4 ng/dL at 90 days post-treatment; PMID 32469183, 38143206). In women, ovarian estrogen suppression induced by leuprolide resolves endometriosis lesions and fibroid volume, and eliminates the hormonal cycling underlying PMDD symptoms. The mechanism is fully reversible — testosterone and estrogen levels return toward normal after treatment cessation, though recovery is slower than with short-acting GnRH antagonists.

Class: GnRH agonist / luteinizing hormone-releasing hormone (LHRH) agonist — synthetic nonapeptide

What it's studied for

• Androgen deprivation therapy (ADT) for prostate cancer — biochemically recurrent disease Phase III RCT
  • Phase 3 EMBARK trial (N=1068, median follow-up 60.7 months). Leuprolide alone (every 12 weeks) achieved 5-year metastasis-free survival (MFS) of 71.4% (95% CI 65.7–76.3). Combination of enzalutamide + leuprolide was superior (MFS 87.3%; HR 0.42, 95% CI 0.30–0.61; P<0.001). Enzalutamide monotherapy was also superior to PMID 37851874 Shore et al. (EMBARK), N Engl J Med 2023
  • EMBARK final OS analysis (N=1068). 8-year overall survival was 69.5% with leuprolide alone vs 78.9% with enzalutamide + leuprolide (HR for death 0.60, 95% CI 0.44–0.80; P<0.001). Enzalutamide monotherapy 8-year OS 73.1% — not significantly different from leuprolide alone. Establishes leuprolide + enzalutamide as a new PMID 41124201 Armstrong et al. (EMBARK OS), N Engl J Med 2026
  • EMBARK secondary endpoints: enzalutamide + leuprolide vs leuprolide alone at 5 years showed improved freedom from distant metastasis (91.0% vs 81.5%), castration resistance-free survival (96.6% vs 67.8%), and symptomatic progression-free survival (70.9% vs 53.3%). Quality-of-life deterioration was minimal and comparabl PMID 41364813 Freedland et al. (EMBARK secondary endpoints), J Urol 2026
  • EMBARK post hoc analysis stratified by age (<70 vs ≥70 years; N=1068). MFS benefit of enzalutamide ± leuprolide was preserved regardless of age. Treatment-related serious adverse events (TRSAEs) were 0.6–11.7% across all groups, with slightly higher rates in patients ≥70 years but low in all groups. PMID 41274168 Sweeney et al. (EMBARK age subgroup), Eur J Cancer 2026
  • PRO analysis of EMBARK (N=1068). Leuprolide alone maintained high baseline health-related quality of life; median time to first confirmed clinically meaningful deterioration in worst pain was 19.35 months with leuprolide alone. Both enzalutamide arms preserved QoL comparable to leuprolide alone over median 60-month fol PMID 38320501 Sternberg et al. (EMBARK QoL), NEJM Evidence 2023
• Androgen deprivation therapy for advanced/metastatic prostate cancer — testosterone suppression benchmark Phase III RCT
  • Phase 3 HERO trial (N=930; leuprolide n=308, relugolix n=622). Leuprolide injections every 3 months achieved sustained castration in 88.8% of men over 48 weeks. On day 4, 0% of leuprolide patients had reached castrate testosterone (vs 56% with relugolix). Major adverse cardiovascular events occurred in 6.2% of leuproli PMID 32469183 Shore et al. (HERO trial), N Engl J Med 2020
  • HERO recovery subgroup (N=184 evaluable). At 90 days post-treatment, mean testosterone was 58.6 ng/dL in leuprolide-treated men vs 288.4 ng/dL in relugolix-treated men. Only 3.2% of leuprolide-treated patients recovered testosterone >280 ng/dL by day 90 vs 54% with relugolix. Median time to testosterone recovery 112 da PMID 38143206 Shore et al. (HERO testosterone recovery), Eur Urol Oncol 2024
• Comparison with GnRH antagonist degarelix for prostate cancer ADT Phase III RCT
  • Phase 3 RCT (N=610; 1-year study). Leuprolide 7.5 mg IM monthly achieved castration (testosterone ≤0.5 ng/mL) in 96.4% of patients; degarelix groups 97.2–98.3%. Leuprolide required antiandrogen supplements to prevent clinical flare due to initial testosterone surge; none of the leuprolide-treated patients reached castr PMID 19035858 Klotz et al., BJU International 2008
• Endometriosis — pain relief and cyst recurrence prevention after fertility-preserving surgery Systematic review of RCTs
  • Network meta-analysis of RCTs evaluating post-surgical hormonal therapy for endometriosis. Leuprolide, compared to placebo, significantly reduced cyst recurrence rate and improved symptom effectiveness after fertility-preserving surgery. In cases with fertility requirements, leuprolide was superior to danazol and gestr PMID 37543781 Ye et al., Medicine (Baltimore) 2023
• PMDD (premenstrual dysphoric disorder) — diagnostic tool and ovarian suppression therapy Human RCT (controlled experimental design)
  • Controlled study (N=34 women with PMDD, N=76 healthy comparators). Leuprolide-induced ovarian suppression eliminated affective symptom cyclicity in women with PMDD. PMDD symptoms (anxiety, sadness, irritability, mood swings) recurred during estradiol and progesterone addback in PMDD patients but not in healthy comparat PMID 41030005 Schmidt et al., Am J Psychiatry 2025
• Gender-affirming puberty suppression in gender-diverse youth Retrospective cohort / safety study
  • Retrospective chart review (N=33 gender-diverse youth, ages 9–18, mean 13.7 years) at a tertiary Canadian center. Mean post-leuprolide QTc was 415 ms (SD 27, range 372–455 ms); none of the 33 patients developed clinically significant QTc prolongation (>460 ms). Only 24.2% had borderline QTc (440–460 ms). Supports cardi PMID 36895314 Power et al., Transgend Health 2023
• Pharmaceutical formulation / drug delivery across multiple indications Review / expert opinion
  • Review of leuprolide formulations. Marketed depot formulations include 1-month (3.75 mg, 7.5 mg), 3-month (11.25 mg, 22.5 mg), 4-month (30 mg), 6-month (45 mg) IM/SC depot injections, and a 12-month subcutaneous implant (Viadur). Oral and intranasal delivery strategies under investigation due to poor bioavailability of PMID 22335366 Sartor, Expert Opin Drug Deliv 2012

Safety signals

• Testosterone/estrogen 'flare' on initiation
• Increased major adverse cardiovascular events (MACE) with long-term ADT
• Bone mineral density loss and osteoporosis risk
• Prolonged testosterone suppression after treatment cessation
• Metabolic syndrome features: weight gain, muscle loss, insulin resistance
• Pituitary apoplexy (rare)
• Leuprolide-induced myopathy
• Hot flushes — most common side effect

Contraindications

Community-reported dosing

All studies (13)

• PMID 19035858 Phase III RCT
  Comparison with GnRH antagonist degarelix for prostate cancer ADT
• PMID 22335366 Review / expert opinion
  Pharmaceutical formulation / drug delivery across multiple indications
• PMID 31643987
• PMID 32469183 Phase III RCT
  Androgen deprivation therapy for advanced/metastatic prostate cancer — testosterone suppression benc
• PMID 36895314 Retrospective cohort / safety study
  Gender-affirming puberty suppression in gender-diverse youth
• PMID 37543781 Systematic review of RCTs
  Endometriosis — pain relief and cyst recurrence prevention after fertility-preserving surgery
• PMID 37851874 Phase III RCT
  Androgen deprivation therapy (ADT) for prostate cancer — biochemically recurrent disease
• PMID 38143206 Phase III RCT
  Androgen deprivation therapy for advanced/metastatic prostate cancer — testosterone suppression benc
• PMID 38320501 Phase III RCT
  Androgen deprivation therapy (ADT) for prostate cancer — biochemically recurrent disease
• PMID 41030005 Human RCT (controlled experimental design)
  PMDD (premenstrual dysphoric disorder) — diagnostic tool and ovarian suppression therapy
• PMID 41124201 Phase III RCT
  Androgen deprivation therapy (ADT) for prostate cancer — biochemically recurrent disease
• PMID 41274168 Phase III RCT
  Androgen deprivation therapy (ADT) for prostate cancer — biochemically recurrent disease
• PMID 41364813 Phase III RCT
  Androgen deprivation therapy (ADT) for prostate cancer — biochemically recurrent disease